Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 3
Submit an article Journal homepage
126
Views
0
CrossRef citations to date
0
Altmetric
Review

Update on Intravesical Agents for Non-Muscle-Invasive Bladder Cancer

Shahrokh F Shariat1 Urology Service, Memorial Sloan–Kettering Cancer Center, NY, USA;2 Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY10021, USACorrespondence[email protected]
View further author information
,
Daher C Chade1 Urology Service, Memorial Sloan–Kettering Cancer Center, NY, USAView further author information
,
Pierre I Karakiewicz3 Department of Urology, University of Montréal, Montréal, Quebec, CanadaView further author information
,
Douglas S Scherr2 Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY10021, USAView further author information
&
Guido Dalbagni1 Urology Service, Memorial Sloan–Kettering Cancer Center, NY, USAView further author information
Pages 381-392 | Published online: 10 May 2010

Bibliography

  • Parkin DM : The global burden of urinary bladder cancer.Scand. J. Urol. Nephrol. Suppl.218 , 12–20 (2008).
  • Kirkali Z , ChanT, ManoharanMet al.: Bladder cancer: epidemiology, staging and grading, and diagnosis.Urology66 , 4–34 (2005).
  • Sylvester RJ : Natural history, recurrence, and progression in superficial bladder cancer.Scientific W. J.6 , 2617–2625 (2006).
  • Lotan Y , CapitanioU, ShariatSF, HuttererGC, KarakiewiczPI: Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.BJU Int.103 , 1368–1374 (2009).
  • Lotan Y , BensalahK, RuddellT, ShariatSF, SagalowskyAI, AshfaqR: Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.J. Urol.179 , 2164–2169 (2008).
  • Karakiewicz PI , BenayounS, ZippeCet al.: Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.BJU Int.97 , 997–1001 (2006).
  • Shariat , SF, Casella R, Wians FH Jr et al.: Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur. Urol.45 , 304–313; author reply 313 (2004).
  • Pawinski A , SylvesterR, KurthKHet al.: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.J. Urol.156 , 1934–1940; discussion 1940–1941 (1996).
  • Shariat SF , ZippeC, LudeckeGet al.: Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.J. Urol.173 , 1518–1525 (2005).
  • Crispen R : History of BCG and its substrains.Prog. Clin. Biol. Res.310 , 35–50 (1989).
  • Mathe , G, Amiel JL, Schwarzenberg L et al.: Active immunotherapy for acute lymphoblastic leukaemia. Lancet1 , 697–699 (1969).
  • Morton D , EilberFR, MalmgrenRA, WoodWC: Immunological factors which influence response to immunotherapy in malignant melanoma.Surgery68 , 158–163; discussion 163–164 (1970).
  • Zbar B , BernsteinID, GL Bartlett, Hanna MG Jr, Rapp HJ: Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J. Natl Cancer. Inst.49 , 119–130 (1972).
  • Coe JE , FeldmanJD: Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder.Immunology10 , 127–136 (1966).
  • Morales A , EidingerD, BruceAW: Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors.J. Urol.116 , 180–183 (1976).
  • Lamm DL : Bacillus Calmette–Guerin immunotherapy for bladder cancer.J. Urol.134 , 40–47 (1985).
  • Mori K , LammDL, CrawfordED: A trial of bacillus Calmette–Guerin versus adriamycin in superficial bladder cancer: a South-West Oncology Group study.Urol. Int.41 , 254–259 (1986).
  • Herr HW , PinskyCM, WhitmoreWF Jr, Oettgen HF, Melamed MR: Effect of intravesical bacillus Calmette–Guerin (BCG) on carcinoma in situ of the bladder. Cancer51 , 1323–1326 (1983).
  • Herr HW , PinskyCM, WhitmoreWF Jr, Sogani PG, Oettgen HF, Melamed MR: Experience with intravesical bacillus Calmette–Guerin therapy of superficial bladder tumors. Urology25 , 119–123 (1985).
  • Yoneyama T , OhyamaC, ImaiAet al.: Low-dose instillation therapy with bacille Calmette–Guerin Tokyo 172 strain after transurethral resection: historical cohort study.Urology71 , 1161–1165 (2008).
  • Sylvester RJ , van der MA, Lamm DL: Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168 , 1964–1970 (2002).
  • Martinez-Pineiro JA , Martinez-PineiroL, SolsonaEet al.: Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.J. Urol.174 , 1242–1247 (2005).
  • Zlotta AR , van Vooren JP, Huygen K et al.: What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur. Urol.37 , 470–477 (2000).
  • de Boer EC , RooyakkersSJ, SchamhartDH, de Reijke TM, Kurth KH: BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur. Urol.48 , 333–338 (2005).
  • Melekos MD , ChionisH, PantazakosA, FokaefsE, ParanychianakisG, DauaherH: Intravesical bacillus Calmette–Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule.J. Urol.149 , 744–748 (1993).
  • Krege S , GianiG, MeyerR, OttoT, RubbenH: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette–Guerin. Participating clinics.J. Urol.156 , 962–966 (1996).
  • Iantorno R , NicolaiM, MastroprimianoGet al.: Randomized prospective study comparing long-term intravesical instillation of BCG after transurethral resection and transurethral resection alone in patients with superficial bladder cancer.J. Urol.161(Suppl.) , 284 (1999).
  • Lamm DL : Long-term results of intravesical therapy for superficial bladder cancer.Urol. Clin. N. Am.19 , 573–580 (1992).
  • Millan-Rodriguez , F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol.163 , 73–78 (2000).
  • Shelley MD , CourtJB, KynastonH, WiltTJ, FishRG, MasonM: Intravesical bacillus Calmette–Guerin in Ta and T1 bladder cancer.Cochrane Database Syst. Rev.CD001986 (2000).
  • Witjes JA , FransenMP, van der Meijden AP, Doesburg WH, Debruyne FM: Use of maintenance intravesical bacillus Calmette–Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study. Urol. Int.51 , 67–72 (1993).
  • Han RF , PanJG: Can intravesical bacillus Calmette–Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.Urology67 , 1216–1223 (2006).
  • Joudi FN , SmithBJ, O‘DonnellMA: Final results from a national multicenter Phase II trial of combination bacillus Calmette–Guerin plus interferon a-2B for reducing recurrence of superficial bladder cancer.Urol. Oncol.24 , 344–348 (2006).
  • Herr HW , DonatSM, DalbagniG: Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?J. Urol.177 , 75–79; discussion 79 (2007).
  • Hudson MA , RatliffTL, GillenDPet al.: Single course versus maintenance bacillus Calmette–Guerin therapy for superficial bladder tumors: a prospective, randomized trial.J. Urol.138 , 295–298 (1987).
  • Badalament RA , HerrHW, WongGYet al.: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette–Guerin therapy of superficial bladder cancer.J. Clin. Oncol.5 , 441–449 (1987).
  • Palou J , LagunaP, Millan-RodriguezF, HallRRet al.: Control group and maintenance treatment with bacillus Calmette–Guerin for carcinoma in situ and/or high grade bladder tumors.J. Urol.165 , 1488–1491 (2001).
  • Lamm DL , BlumensteinBA, CrissmanJDet al.: Maintenance bacillus Calmette–Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.J. Urol.163 , 1124–1129 (2000).
  • Böhle A , JochamD, BockPR: Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.J. Urol.169 , 90–95 (2003).
  • Malmström PU , SylvesterRJ, CrawfordDEet al.: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette–Guerin for non-muscle-invasive bladder cancer.Eur. Urol.56 , 247–256 (2009).
  • Herr HW : Is maintenance bacillus Calmette–Guerin really necessary?Eur. Urol.54 , 971–973 (2008).
  • Sylvester RJ , van der Meijden AP, Witjes JA, Kurth K: Bacillus Calmette–Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174 , 86–91; discussion 91–92 (2005).
  • Orihuela E , HerrHW, PinskyCM, WhitmoreWF Jr: Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer60 , 326–333 (1987).
  • Berry DL , BlumensteinBA, MagyaryDL, LammDL, CrawfordED: Local toxicity patterns associated with intravesical bacillus Calmette–Guerin: a Southwest Oncology Group study.Int J. Urol.3 , 98–100; discussion 101 (1996).
  • Shoenfeld Y , Aron-MaorA, TanaiA, EhrenfeldM: BCG and autoimmunity: another two-edged sword.J. Autoimmun.16 , 235–240 (2001).
  • van der Meijden AP , SylvesterRJ, OosterlinckW, HoeltlW, BonoAV: Maintenance bacillus Calmette–Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial.Eur. Urol.44 , 429–434 (2003).
  • Rischmann P , DesgrandchampsF, MalavaudB, ChopinDK: BCG intravesical instillations: recommendations for side-effects management.Eur. Urol.37(Suppl. 1) , 33–36 (2000).
  • Koya MP , SimonMA, SolowayMS: Complications of intravesical therapy for urothelial cancer of the bladder.J. Urol.175 , 2004–2010 (2006).
  • Malmstrom PU , WijkstromH, LundholmC, WesterK, BuschC, NorlenBJ: 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette–Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.J. Urol.161 , 1124–1127 (1999).
  • Bilen CY , InciK, ErkanI, OzenH: The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette–Guerin.J. Urol.169 , 1702–1705 (2003).
  • DeVeale B , BrummelT, SeroudeL: Immunity and aging: the enemy within?Aging Cell3 , 195–208 (2004).
  • Heiner JG , TerrisMK: Effect of advanced age on the development of complications from intravesical bacillus Calmette–Guerin therapy.Urol. Oncol.26 , 137–140 (2008).
  • Nilsson S , RagnhammarP, GlimeliusB, NygrenP: A systematic overview of chemotherapy effects in urothelial bladder cancer.Acta Oncol.40 , 371–390 (2001).
  • Thrasher JB , CrawfordED: Complications of intravesical chemotherapy.Urol. Clin. North Am.19 , 529–539 (1992).
  • Gao X , AuJL, BadalamentRA, WientjesMG: Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.Clin. Can. Res.4 , 139–143 (1998).
  • Au JL , BadalamentRA, WientjesMGet al.: Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial.J. Natl Cancer Instit.93 , 597–604 (2001).
  • Huncharek M , GeschwindJF, WitherspoonB, McGarryR, AdcockD: Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials.J. Clin. Epidemiol.53 , 676–680 (2000).
  • Huncharek M , McGarryR, KupelnickB: Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.Anticancer Res.21 , 765–769 (2001).
  • Lamm DL , RiggsDR, TraynelisCL, NseyoUO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.J. Urol.153 , 1444–1450 (1995).
  • Sylvester RJ , OosterlinckW, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171 , 2186–2190; quiz 2435 (2004).
  • Dalbagni G , RussoP, SheinfeldJet al.: Phase I trial of intravesical gemcitabine in bacillus Calmette–Guerin-refractory transitional-cell carcinoma of the bladder.J. Clin. Oncol.20 , 3193–3198 (2002).
  • Dalbagni G , RussoP, BochnerBet al.: Phase II trial of intravesical gemcitabine in bacille Calmette–Guerin-refractory transitional cell carcinoma of the bladder.J. Clin. Oncol.24 , 2729–2734 (2006).
  • Laufer M , RamalingamS, SchoenbergMPet al.: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a Phase I and pharmacokinetic study.J. Clin. Oncol.21 , 697–703 (2003).
  • De Berardinis E , AntoniniG, PetersGJet al.: Intravesical administration of gemcitabine in superficial bladder cancer: a Phase I study with pharmacodynamic evaluation.BJU Int.93 , 491–494 (2004).
  • McKiernan JM , MassonP, MurphyAMet al.: Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.J. Clin. Oncol.24 , 3075–3080 (2006).
  • Laudano MA , BarlowLJ, MurphyAMet al.: Long-term clinical outcomes of a Phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.Urology75(1) , 134–137 (2009).
  • Lamm DL , BlumensteinBA, CrawfordEDet al.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette–Guerin for transitional-cell carcinoma of the bladder.N. Engl. J. Med.325 , 1205–1209 (1991).
  • Shelley MD , WiltTJ, CourtJet al.: Intravesical bacillus Calmette–Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.BJU Int.93 , 485–490 (2004).
  • Hall MC , ChangSS, DalbagniGet al.: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.J. Urol.178 , 2314–2330 (2007).
  • Ojea A , NogueiraJL, SolsonaEet al.: A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette–Guerin (27 mg) versus very low-dose bacillus Calmette–Guerin (13.5 mg) versus mitomycin C.Eur. Urol.52 , 1398–1406 (2007).
  • Friedrich MG , PichlmeierU, SchwaiboldH, ConradS, HulandH: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette–Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma.Eur. Urol.52 , 1123–1129 (2007).
  • Böhle A , BockPR: Intravesical bacille Calmette–Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.Urology63 , 682–686; discussion 686–687 (2004).
  • Huncharek M , KupelnickB: The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette–Guerin immunotherapy.Am. J. Clin. Oncol.27 , 522–528 (2004).
  • Huland H , KloppelG, FeddersenIet al.: Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients.J. Urol.144 , 68–71; discussion 71–72 (1990).
  • Bouffioux C , KurthKH, BonoAet al.: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.J. Urol.153 , 934–941 (1995).
  • Okamura K , KinukawaT, TsumuraYet al.: A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.Eur. Urol.33 , 285–288; discussion 289 (1998).
  • Koga H , KuroiwaK, YamaguchiA, OsadaY, TsuneyoshiM, NaitoS: A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.J. Urol.171 , 153–157 (2004).
  • Conrad S , FriedrichMG, SchwaiboldH: Long term prophylaxis with mitomycin C (MMC) further reduces tumor recurrence compared with short term prophylaxis with MMC or bacillus Calmette–Guerin (BCG).J. Urol.171 , 271 (2004).
  • Cookson MS , HerrHW, ZhangZF, SolowayS, SoganiPC, FairWR: The treated natural history of high risk superficial bladder cancer: 15-year outcome.J. Urol.158 , 62–67 (1997).
  • Herr HW , DalbagniG: Defining bacillus Calmette–Guerin refractory superficial bladder tumors.J. Urol.169 , 1706–1708 (2003).
  • Luo Y , ChenX, O‘DonnellMA: Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect.Cytokine21 , 17–26 (2003).
  • Morales A , PhadkeK, SteinhoffG: Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed.J. Urol.181 , 1040–1045 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.